Dr Kevin Shannon speaks with ecancertv at BSH 2016 about heritable risks for leukaemia.

Familial history of leukaemia has only recently been elucidated using genomic high-throughput techniques to identify the upregulation of certain genes, notably GATA2, AML1 and RUNX1.

Dr Shannon describes the considerations clinicians and patients might experience when discovering they have a strong likelihood of passing on this predisposition. 

ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.